15 reports

  • ONCOLOGICAL PRURITUS

Being a dermatological condition, the topical formulation can give good local relief from itching sensations.

  • Dermatological Condition
  • Allergan plc
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi S.A.
  • 2.6.3 Psoriasis

The introduction of topical corticosteroids in 1952 was the most significant milestone in the history of dermatological condition therapy.

  • Dermatological Condition
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.

The introduction of topical corticosteroids in 1952 was the most significant milestone in the history of dermatological condition therapy.

  • Dermatological Condition
  • World
  • Market Size
  • Amgen Inc.
  • Biologics, Inc.
  • Clinical and Commercial Landscape
  • 4.4.3 Psoriasis

Approximately one third of the US population suffers from at least one active dermatological condition (Johnson, 2004).

  • Dermatological Condition
  • World
  • Market Size
  • Allergan plc
  • Apricus Biosciences, Inc.
  • 1.1 - Executive Summary

GMR DATA - TO WHAT EXTENT ARE DERMATOLOGY MEDICAL DEVICES AFFECTING THE DERMATOLOGICAL DRUGS SECTOR; WHAT ARE THE CONDITION/ S FOR WHICH DEVICES ARE USED?

  • Dermatological Condition
  • World
  • Forecast
  • Allergan plc
  • Valeant Pharmaceuticals International, Inc.
  • Latest Clinical Trials News on Epidermolysis Bullosa

EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies.

  • Dermatological Condition
  • Dermatology
  • World
  • Product Initiative
  • Amryt Pharma plc
  • FEATURED NEWS & PRESS RELEASES

" Studying A-## in a second dermatological condition, in addition to our ongoing work in seborrheic keratosis, is an important milestone as we continue to expand our development pipeline. "

  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment...
  • FEATURED NEWS & PRESS RELEASES

" Studying A-## in a second dermatological condition, in addition to our ongoing work in seborrheic keratosis, is an important milestone as we continue to expand our development pipeline. "

  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • AMG-0101 - DRUG PROFILE

There was no statistically significant difference between the NF-kappaB Decoy Oligonucleotide treated group and the placebo group in the primary end point of the improvement in the dermatological condition scores at week ##.

  • Dermatological Condition
  • Pathology
  • Pharmaceutical
  • United States
  • Product Initiative
  • Latest Clinical Trials News on Atopic Dermatitis

" We now have an opportunity to further evaluate the unique range of pharmacological attributes of EISO in treating this important dermatological condition. "

  • Clinical Trial
  • Dermatological Condition
  • Pharmaceutical
  • World
  • Product Initiative
  • APR 20, 2017: XBIOTECH ANNOUNCES OUTCOME OF EMA'S ORAL EXPLANATION MEETING

EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies.

  • Dermatological Condition
  • Monoclonal Antibody
  • World
  • Product Initiative
  • XBiotech Inc.

The company' s lead product candidate, bertilimumab, is under clinical development for moderate to severe ulcerative colitis, crohn' s disease and bullous pemphigoid, an orphan auto-immune dermatological condition.

  • Dermatological Condition
  • United States
  • Company
  • Product Initiative
  • Pfizer Inc.
  • Epidermolysis Bullosa - Product Development Milestones

EB is a chronic and debilitating condition for which there is currently no known cure.

  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Product Development Milestones

The American Academy of Dermatology calls acne the " most common skin condition in the United States, " affecting ## to ## million Americans.

  • Autoimmune Disease
  • Dermatological Condition
  • United States
  • Product Initiative
  • Valeant Pharmaceuticals International, Inc.
  • AMG-0101 - DRUG PROFILE

The drug candidate by inhibiting kinase enzyme ameliorates the condition.

  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative